HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

<ul>
<li>Thirteen important departments formulated the “Work Plan for Supporting the High-quality Development of State-owned Enterprise (SOE)-run Medical Institutions”(the “Work Plan”), which reflects a significant change in government's attitude towards SOE-run hospitals.</li>
<li>The core goal of “Work Plan” is to make public medical system bigger and stronger.Changes will occur with the participation of central enterprises. It's time to change the thinking mode.</li>
<li>Government-Run hospitals/SOE-run hospitals are still the main force of China's medical service market. Their status will be higher than that of private hospitals, whose development space would be further squeezed.</li>
</ul>


Thirteen important departments formulated the “Work Plan for Supporting the High-quality Development of State-owned Enterprise (SOE)-run Medical Institutions”(the “Work Plan”), which reflects a significant change in government's attitude towards SOE-run hospitals.
The core goal of “Work Plan” is to make public medical system bigger and stronger.Changes will occur with the participation of central enterprises. It's time to change the thinking mode.
Government-Run hospitals/SOE-run hospitals are still the main force of China's medical service market. Their status will be higher than that of private hospitals, whose development space would be further squeezed.


Reform in China's Medical Service Industry: SOE-Run Hospitals Usher in a Critical Turning Point

Macro & Asian equity Technical Strategies, BBSP Asia

Federico D'Inca

Macro & Asian equity Technical Strategies

BBSP Asia

Technical Analysis

Long-Term Allocation (Strategic view) in terms of Relative Value vs MXAP • NIKKEI/MXAP: Long-term outperformance still expected. • ASX/MXAP: Outperformance expected holding above long-term support (from 2003). • TWSE/MXAP: Neutral at the moment, watching closely a key level (2.22) to surpass to confirm TWSE long-term outperformance vs MXAP. • KOSPI/MXAP: Long-term outperformance in progress/still expected. • HSI/MXAP: Long-term outperformance in progress/still expected. • HSCEI/MXAP: Long-term…

Long-Term Allocation (Strategic view) in terms of Relative Value vs MXAP • NIKKEI/MXAP: Long-term outperformance still expected. • ASX/MXAP: Outperformance expected holding above long-term support (from 2003). • TWSE/MXAP: Neutral at the moment, watching closely a key level (2.22) to surpass to confirm TWSE long-term outperformance vs MXAP.  • KOSPI/MXAP: Long-term outperformance in progress/still expected. • HSI/MXAP: Long-term outperformance in progress/still expected. • HSCEI/MXAP: Long-term…

BBSP Equity Asia Weekly Research 25 Oct 2017

Mid Term Country Allocation (Tactical view) in terms of Relative Value vs MXAPWhat's new from last week • Although ASX remains within its 3-month range (below 5775) the ratio ASX/MXAP drifted to key support for an expected bounce reaction. Therefore, giving bias for ASX to shape a bullish exit from its range and outperform MXAP. (ref new AU strategies). • Rating unchanged for the rest of the countries. Outperformance in progress for Japan (Nikkei), Korea (Kospi) and HK, China (HSI, HSCEI). Still…

Mid Term Country Allocation (Tactical view) in terms of Relative Value vs MXAPWhat's new from last week • Although ASX remains within its 3-month range (below 5775) the ratio ASX/MXAP drifted to key support for an expected bounce reaction. Therefore, giving bias for ASX to shape a bullish exit from its range and outperform MXAP. (ref new AU strategies). • Rating unchanged for the rest of the countries. Outperformance in progress for Japan (Nikkei), Korea (Kospi) and HK, China (HSI, HSCEI). Still…

Equity Asia Weekly Research - 11 Oct 2017

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>We analyzed the performance of Hong Kong Connect implementation in March 2026.</li>
<li>ADD stocks reversed their bridge window drawdown at implementation. The bounce faded by week 3 to 4.</li>
<li>DELETE stocks fell through first week, exceeding Sep 2025. Within the DELETE basket, the names where connect investors sold the most also fell the most.</li>
</ul>


We analyzed the performance of Hong Kong Connect implementation in March 2026.
ADD stocks reversed their bridge window drawdown at implementation. The bounce faded by week 3 to 4.
DELETE stocks fell through first week, exceeding Sep 2025. Within the DELETE basket, the names where connect investors sold the most also fell the most.


HSCI / HK Connect (March 2026) Post-Event Review: What Worked, What Didn't

Bespoke Research on China and neighbouring regions, Bixmoor

Bixmoor

Bespoke Research on China and neighbouring regions

Bixmoor specialises in providing bespoke research to business, governments and the financial community on China and neighbouring regions. We seek to build long-term relationships with our clients, based on our expertise, our reliability and our determination to find the right solution.

By allowing couples to have up to two children China hopes to reverse its likely population decline. But falling fertility and the pressures of urban living mean that existing policies are unlikely to deliver a baby boom.

By allowing couples to have up to two children China hopes to reverse its likely population decline. But falling fertility and the pressures of urban living mean that existing policies are unlikely to deliver a baby boom.

Falling Fertility Adds to China's Population Woes

China

China Resources Medical Holdings provides comprehensive healthcare services, hospital management, and group purchasing organization businesses in Mainland China. It operates a network of medical institutions, offering outpatient and inpatient services, as well as supply chain and operational management services to affiliated hospitals. The company is headquartered in Beijing, China, and was founded in 2013.

China Resources Medical Holdings (1515 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

China Resources Medical Holdings (1515 HK)

Reform in China's Medical Service Industry: SOE-Run Hospitals Usher in a Critical Turning Point

Government's attitude towards SOE-run hospitals has a significant change as new policy is released,aiming to make public medical system bigger...

Xinyao (Criss) Wang

BBSP Equity Asia Weekly Research 25 Oct 2017

Long-Term Allocation (Strategic view) in terms of Relative Value vs MXAP• NIKKEI/MXAP: Long-term outperformance still expected.• ASX/MXAP:...

BBSP Asia

Equity Asia Weekly Research - 11 Oct 2017

Mid Term Country Allocation (Tactical view) in terms of Relative Value vs MXAPWhat's new from last week• Although ASX remains within its 3-month...

BBSP Asia

HSCI / HK Connect (March 2026) Post-Event Review: What Worked, What Didn't

HK Connect Mar 2026 implementation cycle is completing. ADD reversed the WAI drawdown at implementation. DELETE continuation worked post...

Ke Yan, CFA, FRM

Falling Fertility Adds to China's Population Woes

By allowing couples to have up to two children China hopes to reverse its likely population decline. But falling fertility and the pressures of...

Bixmoor

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)